JDD Corner

Hand Foot Skin Reaction Associated With Palbociclib
Palbociclib
by NEXT STEPS IN DERM TEAM on
INTRODUCTION Palbociclib is one of three new small-molecule inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) approved for use in the treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (Her2-) advanced or metastatic breast cancer. CDK4/6 inhibitors have a good overall safety profile but reported side effects include cytopenias, diarrhea, QTc pr …
Special Focus on Acne and Rosacea
Acne and Rosacea
by NEXT STEPS IN DERM TEAM on
The June issue of the Journal of Drugs in Dermatology focuses on the topics of acne and rosacea, and features additional articles on topics such as atopic dermatitis and psoriasis. Straight from the JDD Editor’s desk, we share this month’s issue highlights: Guest Editor James Q. Del Rosso discusses roadblocks that impede patient ability to obtain medications selected by their dermatologist …
Treatment of Periorificial Dermatitis With Novel Narrow Spectrum Sarecycline
Periorificial Dermatitis
by NEXT STEPS IN DERM TEAM on
Broad spectrum tetracyclines are a well-known, widely used, and often successful treatment for use in inflammatory skin pathologies such as acne and rosacea. However, the steady rise of antibiotic resistance and gut dysbiosis associated with broad spectrum tetracyclines emphasizes the importance and responsibility of antibiotic stewardship. Narrow spectrum antibiotics have become increasingly impo …
From Port-Wine Stain Treatments to Bovine Colostrum, Telomeres, and Skin Aging
Port-Wine Stain
by NEXT STEPS IN DERM TEAM on
The May issue of the Journal of Drugs in Dermatology features dermatology articles on topics ranging from treatment updates on Port-Wine stain to the protective effect that liposomal bovine colostrum exerts on skin aging using telomere length as an aging biomarker. Straight from the JDD Editor’s desk, we share this month’s issue highlights: Authors analyze extrusion forces of various produ …
Prescribing Isotretinoin for Transgender Patients
isotretinoin for transgender patients
by NEXT STEPS IN DERM TEAM on
Case Scenario A 26-year-old patient presents to the dermatology clinic with severe nodulocystic scarring acne. The patient identifies as a transgender male and notes that he has been receiving hormone replacement therapy for the past 4 years with weekly intramuscular testosterone injections. He has not had any gender-affirming surgeries and reports being currently amenorrhoeic. He is curren …